Senlang Biotechnology announced the successful closing of RMB 200 million from Qianhai Ark Asset Management.

CEC Capital Group acted as the exclusive financial advisor for Senlang Biotechnology in this transaction.

Senlang Biotechnology is an advanced biopharmaceutical firm focused on pioneering new technologies in immunotherapy for the targeted treatment of malignant tumors. The capital secured in this funding round will primarily advance the company's current pipeline, facilitate the research and development for new products, and upgrade and iterate their technological platforms. Senlang Biotechnology remains committed to building a comprehensive cell therapy ecosystem, encompassing upstream technological research and development, intermediate-level manufacturing of cell-based products, and downstream clinical applications.